Early data from the Phase II/III FOCUS study found that Mateon Therapeutics Inc.’s CA4P (fosbretabulin) had a non-significant effect on progression-free survival (PFS) in patients with platinum-resistant ovarian cancer, and the number of partial responses were lower in the treated arm compared with the control arm of the study.
Company executives were not discouraged by the results, however. The data came from the second interim analysis of the FOCUS trial, and president and CEO William Schwieterman said he was...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?